Shionogi is buying rare disease biotech IntraBio for $2 billion

The Japanese drugmaker will gain global rights to Aqneursa, a drug approved in the U.S. and E.U. for two inherited neurological disorders

MediaNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (qz.com)